HC Wainwright reiterated their buy rating on shares of Abeona Therapeutics (NASDAQ:ABEO) in a research note published on Wednesday, November 22nd. The brokerage currently has a $30.00 price target on the biopharmaceutical company’s stock.
A number of other equities analysts have also commented on the stock. Maxim Group set a $17.00 price target on shares of Abeona Therapeutics and gave the stock a buy rating in a research report on Tuesday, August 29th. SunTrust Banks assumed coverage on shares of Abeona Therapeutics in a research report on Wednesday, November 8th. They set a buy rating and a $26.00 price target on the stock. Citigroup assumed coverage on shares of Abeona Therapeutics in a research note on Tuesday, October 10th. They set a buy rating and a $32.00 price objective on the stock. Cantor Fitzgerald reiterated a buy rating and set a $21.00 price objective on shares of Abeona Therapeutics in a research note on Friday, October 6th. Finally, BidaskClub downgraded shares of Abeona Therapeutics from a strong-buy rating to a buy rating in a research note on Thursday, July 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company’s stock. Abeona Therapeutics currently has a consensus rating of Buy and a consensus target price of $26.10.
Abeona Therapeutics (ABEO) opened at $15.80 on Wednesday. Abeona Therapeutics has a 1 year low of $4.05 and a 1 year high of $22.75.
Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05. Abeona Therapeutics had a negative net margin of 2,946.58% and a negative return on equity of 27.69%. The business had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.22 million. sell-side analysts expect that Abeona Therapeutics will post -0.6 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently bought and sold shares of ABEO. State of Wisconsin Investment Board acquired a new stake in shares of Abeona Therapeutics in the 2nd quarter valued at approximately $122,000. Rhumbline Advisers bought a new position in Abeona Therapeutics in the 2nd quarter valued at approximately $190,000. Bank of New York Mellon Corp raised its holdings in Abeona Therapeutics by 125.8% in the 1st quarter. Bank of New York Mellon Corp now owns 41,929 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 23,358 shares during the last quarter. Schwab Charles Investment Management Inc. bought a new position in Abeona Therapeutics in the 2nd quarter valued at approximately $264,000. Finally, California State Teachers Retirement System bought a new position in Abeona Therapeutics in the 2nd quarter valued at approximately $275,000. Institutional investors own 41.95% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Abeona Therapeutics (ABEO) Rating Reiterated by HC Wainwright” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/08/abeona-therapeutics-abeo-buy-rating-reiterated-at-hc-wainwright.html.
About Abeona Therapeutics
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Ratings for Abeona Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.